Ex-vivo treatment of immunological disorders with pkc-theta...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/505 (2006.01) A61K 39/00 (2006.01) A61P 37/00 (2006.01)

Patent

CA 2760305

Disclosed is a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis. Specifically, the invention relates to a method of treating an immunological disorder or atherosclerosis in a patient comprising treating blood from the patient, or a defined component of said blood, with an inhibitor of PKC-theta ex vivo and then re-administering the treated blood to the patient.

L'invention porte sur un procédé de traitement d'une pluralité de maladies et de troubles qui sont à médiation ou entretenus par l'activité de PKC-thêta, comprenant des troubles immunologiques et une athérosclérose. Spécifiquement, l'invention porte sur un procédé de traitement d'un trouble immunologique ou d'une athérosclérose dans un patient comprenant le traitement ex vivo de sang provenant du patient ou d'un composant défini dudit sang, par un inhibiteur de PKC-thêta puis la réadministration du sang traité au patient.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Ex-vivo treatment of immunological disorders with pkc-theta... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ex-vivo treatment of immunological disorders with pkc-theta..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ex-vivo treatment of immunological disorders with pkc-theta... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1708041

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.